Patent Application
20130309187
The present invention relates to the use of 3-hydroxy-2-pyrone for a skin-whitening agent, a tyrosinase activity inhibitor, and a melanin production inhibitor.
In general, pigmentation on the skin, such as blemishes, is considered to occur upon activation of melanocytes caused by ultraviolet stimulation and enhanced biosynthesis of melanin pigments. Accordingly, many substances that suppress the biosynthesis of melanin pigments have been developed as skin-whitening agents.
It is well known that ascorbic acid has skin-whitening effects for inhibiting melanin synthesis in cells due to the inhibition of tyrosinase activity. However, ascorbic acid disadvantageously is degraded in an aqueous solution and causes coloration, such as browning. In order to overcome such disadvantages, many ascorbic acid derivatives that are more stable in aqueous solutions have been developed. Such derivatives are compounds resulting from esterification of ascorbic acid via introduction of a phosphate group, fatty acid such as stearic acid, or sugar such as glucose into a hydroxyl group at position 2, 3, 5, or 6 of the ascorbic acid. Such derivatives are expected to function in such a manner that they would be absorbed by an organism, hydrolyzed with enzymes to generate ascorbic acid, and thereby exert skin-whitening effects in an organism. These derivatives, however, are problematic in terms of solubility in various solvents, and, disadvantageously, they do not function without being hydrolyzed.
As other substances exerting skin-whitening effects, for example, hydroquinone derivatives, kojic acid and derivatives thereof, and pyrone compounds and derivatives thereof are known (Patent Documents 1 and 2). However, these substances were problematic in terms of solubility in various solvents, skin-whitening effects, and other properties.
Therefore, the development of skin-whitening agents that can exert excellent solubility in various solvents and skin-whitening effects has been desired.
3-Hydroxy-2-pyrone (hereafter it may occasionally be referred to as “3H2P”) is an oxidative degradation product of ascorbic acid, which is reported in Non-Patent Document 1. While it is well known that ascorbic acid is converted into dehydroascorbic acid and diketoglucuronic acid during the process of oxidation, further-oxidized substances are not very well known.
Patent Document 3 and Non-Patent Document 2 describe methods for obtaining 3H2P from ascorbic acid in the form of an oxidative degradation product.
The functions of 3H2P are not very well known, and only a small number of reports have been made concerning 3H2P. Patent Document 3 describes that 3H2P is an amphipathic antioxidant. It reports that 3H2P is excellent in terms of platelet aggregation inhibition and curing of hepatic disorders, and thus that it is usable for a pharmaceutical composition or functional food or beverage product.
Patent Document 1: JP S53-3538 A (1978)
Patent Document 2: JP H04-2562 A (1992)
Patent Document 3: JP 2007-246475 A
Non-Patent Document 1: Bioscience, Biotechnology, and Biochemistry, 69 (11), pp. 2129-2137, 2005
Non-Patent Document 2: N. Morita et al., Bull. Univ. Osaka Pref., Ser. B, Vol. 41, pp. 61-69, 1989
The present invention provides a skin-whitening agent, a tyrosinase activity inhibitor, and a melanin production inhibitor comprising, as an active ingredient, a compound exhibiting excellent solubility in various solvents.
3-Hydroxy-2-pyrone (3H2P) is a compound exhibiting excellent solubility in various solvents. 3H2P has a chemical structure represented by the formula:
3H2P is represented by a molecular formula C5H4O3. The molecular weight thereof is 112.084, its CAS Registry Number is 496-64-0, its systematic name is 3-hydroxy-2-pyrone or 3-hydroxy-2H-pyran-2-one, and its common name is isopyromucic acid. However, no skin-whitening effects of 3H2P were known in the past.
The present inventors discovered that 3H2P has remarkably strong inhibitory effects on tyrosinase activity and inhibitory effects on melanin production and thus is a useful skin-whitening substance. This has led to the completion of the present invention. The present invention includes the following inventions.
The present invention further includes the following inventions.
The present invention provides a skin-whitening agent, a tyrosinase activity inhibitor, and a melanin production inhibitor comprising, as an active ingredient, 3-hydroxy-2-pyrone, which is a compound exhibiting excellent solubility in various solvents.
3-Hydroxy-2-pyrone (3H2P) used in the present invention can be synthesized from dehydroascorbic acid in accordance with the procedure described in, for example, Patent Document 3.
It is not necessary that 3H2P be used in an isolated and purified state. 3H2P is contained in natural products containing ascorbic acid (e.g., acerola) as an oxidative degradation product of ascorbic acid. A natural composition containing 3H2P (e.g., acerola) or a non-natural composition resulting from treatment of such natural composition, so as to adjust the 3H2P concentration to be higher than that of the general natural composition (with 3H2P concentration preferably being at least 0.001%, and more preferably 0.01% to 1.7% by weight, relative to the total amount of the composition) can be used for the present invention.
3H2P may be used in the foam of a solvate, such as a hydrate. When 3H2P is in the form of a solvate, it is preferably a physiologically acceptable solvate (i.e., a solvate that is approved for use in a pharmaceutical, cosmetic, food or beverage, or other form of product).
3H2P has inhibitory effects on tyrosinase activity and inhibitory effects on melanin production in a cell. 3H2P exerts skin whitening effects due to such effects.
Through administration of 3H2P to a subject, such as a human, who desires skin-whitening, skin-whitening can be realized (i.e., skin damage caused by pigmentation, such as blemishes or freckles, can be inhibited or relieved). According to such technique, 3H2P is administered to a subject before pigmentation on the skin occurs due to sunburn, so as to prevent the pigmentation or suppress the progression thereof. Alternatively, 3H2P may be administered to a subject who has already experienced pigmentation, so as to relieve the skin damage caused by pigmentation. Such administration may be implemented for a cosmetic purpose, or it may be implemented by a physician for a medical purpose.
3H2P can be used for a method for the inhibition of tyrosinase activity in vivo or in vitro. The term “inhibition of tyrosinase activity in vivo” refers to the inhibition of tyrosinase activity in an organism, such as a human (and inhibition of tyrosinase activity in skin cells, in particular). The method for the inhibition of tyrosinase activity in vivo may be implemented for a cosmetic purpose, or it may be implemented by a physician for a medical purpose.
3H2P can be used for the prevention or treatment of a disease or symptom that is relieved by the inhibition of tyrosinase activity. Examples of such disease or symptom include blemishes and freckles.
3H2P can be used for the method for the inhibition of melanin production in vivo or in vitro. The term “inhibition of melanin production in vivo” refers to the inhibition of melanin pigment production in an organism, such as a human (and inhibition of melanin production in skin chromocytes, in particular). The method for the inhibition of melanin production in vivo may be implemented for a cosmetic purpose, or it may be implemented by a physician for a medical purpose.
3H2P can be used for the prevention or treatment of a disease or symptom that is relieved by the inhibition of melanin production. Examples of such disease or symptom include blemishes and freckles.
The forms of 3H2P administration to a subject, such as a human, for the purpose of skin-whitening or for the purpose of inhibition of tyrosinase activity or melanin production in vivo are not particularly limited. For example, 3H2P may be administered to the subject via percutaneous administration involving direct application of 3H2P to the target skin (for example, in the form of the external skin preparations described below), oral administration (for example, in the form of powder, tablets, granules, fine grains, liquid, capsules, pills, troches, peroral liquid preparations, suspensions, emulsions, syrups, or elixirs), or parenteral administration other than percutaneous administration (for example, in the form of injection preparations, instillation, suppositories, inhalants, or transmucosal absorbents).
3H2P can be incorporated into an external skin preparation, such as a cosmetic product, quasi-drug, or pharmaceutical product, together with an ingredient that is approved for application to the skin (e.g., other ingredients exhibiting skin-whitening effects, other active ingredients, or ingredients used for the production of preparations), as an active ingredient that exhibits skin-whitening effects, inhibitory effects on tyrosinase activity, or inhibitory effects on melanin production. 3H2P content in the external skin preparation is not particularly limited, provided that 3H2P is able to effectively exhibit skin-whitening effects, inhibitory effects on tyrosinase activity, and/or inhibitory effects on melanin production. Based on the results attained in Experiment 3 and the amounts of active ingredients that can be incorporated into a general external skin preparation, it is preferable that 3H2P content be between 0.0001% and 5% by weight, based on the total amount of the composition for the external skin preparation.
Examples of other ingredients exhibiting skin-whitening effects that can be incorporated into an external skin preparation include ascorbic acid, an ascorbic acid derivative (e.g., a salt of ascorbic acid phosphate ester, a salt of ascorbic acid sulfate ester, ascorbic acid glucoside, or ethyl ascorbic acid), a γ-pyrone glycoside, γ-pyrones such as kojic acid and a kojic acid derivative, and a hydroquinone derivative such as arbutin.
An external skin preparation can be prepared with the use of ingredients that are generally used for the production of cosmetic products, quasi-drugs, or pharmaceutical products. Examples of such ingredients include purified water, alcohols, oil substances, moisturizers, thickeners, preservatives, emulsifiers, crude drug components, ultraviolet absorbers, pigments, aromas, emulsion stabilizers, and pH regulators.
The form of an external skin preparation is not limited, and it may be, for example, a cream, ointment, emulsion, lotion, solution, gel, facial mask, or stick.
Purified water (50 ml) was added to 5.0268 g of dehydroascorbic acid (an oxidation product of ascorbic acid, Wako Pure Chemical Industries, Ltd.) and the mixture was heated at 100° C. for 3 hours to obtain a heat-treated solution.
The resulting heat-treated solution was subjected to extraction with ethyl acetate. The ethyl acetate layer was collected, anhydrous sodium sulfate was added thereto, and the resultant was refrigerated overnight for dehydration. The ethyl acetate layer was concentrated using a rotary evaporator to obtain a fluid concentrate. The fluid concentrate was introduced into a watch glass, a beaker was placed upside-down over the watch glass, the watch glass was heated at 80° C. for 8 hours, and the sublimed components were allowed to adhere to the inside of the beaker. The resultant was dried to collect 293.7 mg of the crystalline sublimate. As a result of analysis of the sublimate by high-performance liquid chromatography (HPLC), the presence of 3-hydroxy-2-pyrone (3H2P) together with 2-furancarboxylic acid (2FA) was observed.
In order to eliminate 2FA, the resulting sublimate (293.7 mg) was dissolved in 8 ml of 0.05% HCl-containing purified water, and the resultant was applied to Sep-Pak C18 (Waters) and eluted with 0.05% HCl-containing purified water and a 0.05% HCl-containing 10% methanol solution, in order to collect a 3H2P-containing fraction. The fraction was concentrated using a rotary evaporator and subjected to extraction with ethyl acetate to collect the ethyl acetate layer. Anhydrous sodium sulfate was added thereto, the mixture was refrigerated for dehydration, the fluid concentrate obtained by evaporation distillation was introduced into a watch glass, a beaker was placed upside-down over the watch glass, the watch glass was heated at 80° C. for 3 hours, and the sublimed 3H2P was allowed to adhere to the inside of the beaker. The resultant was dried to collect 139.9 mg of the crystalline 3H2P. The resulting sublimate was analyzed by HPLC and confirmed to be high-purity 3H2P.
Tyrosinase is known to be an important enzyme that acts when a melanin pigment is produced from tyrosine as an amino acid. Many skin-whitening substances have the inhibitory effects on tyrosinase activity. Thus, the inhibitory effects of kojic acid, ascorbic acid, and 3H2P prepared in Experiment 1 on tyrosinase activity were measured.
In the experiment, 0.2 ml of an enzyme solution containing 72 units/ml tyrosinase (Sigma) was mixed with 1.0 ml of a substrate mixture (i.e., a 2:2:1 mixture of a 6 mM L-DOPA solution, the test composition with the adjusted concentration (hereafter referred to as the “sample”), and phosphate buffer), the absorbance was measured at 475 nm at 37° C. at 0 min and 3 mM, and the inhibition rate of tyrosinase activity was determined using the equation shown below.
Inhibition rate of tyrosinase activity (%)=(1−(the difference in the absorbance of the sample between 0 mM and 3 min)/(the difference in the absorbance of the blank between 0 min and 3 min)×100
The results are shown in
Since the inhibitory effects of 3H2P on tyrosinase activity were confirmed in Experiment 2, inhibitory effects on melanin production in animal cells were further examined. 3H2P prepared in Experiment 1, arbutin, and kojic acid were employed as samples.
B16 mouse melanoma 4A5 cells (RIKEN) were seeded at 5.0 x 104 cells/well on a 6-well plate and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS at 37° C. in the presence of 5% CO2. The medium was exchanged with fresh medium supplemented with the sample on the following day, and culture was conducted in the medium supplemented with the sample for an additional 5 days. The medium was removed 6 days after the initiation of culture, and the cells were collected by using trypsin. The collected cells were suspended in 1N sodium hydroxide, and melanin was extracted via heating. The absorbance of the melanin extract was measured at 405 nm, and the melanin level was quantified with the calibration curve of the melanin reagent (Sigma). In addition, the amount of proteins in the collected cells was determined using the DC Protein Assay KIT (BIO-RAD) and used as the indicator for the viable cell count. Through such measurement, the melanin level and the cell count were determined relative to levels observed in the control not supplemented with the sample, designated as 100. The results are shown in Table 1 and
The inhibitory effects of 3-hydroxy-2-pyrone on tyrosinase activity were compared with those of kojic acid as a γ-pyrone compound, or of coumalin and coumalic acid as α-pyrone compounds. The inhibitory effects of kojic acid, coumalin, and coumalic acid on melanin production are reported in Patent Document 1.
The experiment was carried out in the same manner as that described in Patent Document 1.
An aqueous solution of 1% 3H2P, an aqueous solution of 1% coumalin (Tokyo Chemical Industry Co., Ltd.), an aqueous solution of 1% coumalic acid (Tokyo Chemical Industry Co., Ltd.), and an aqueous solution of 0.01% kojic acid were prepared. Subsequently, 1.45 ml of a substrate-sample mixture comprising an aqueous solution of L-tyrosine (0.3 mg/ml), a sample solution of 3H2P, etc., and McIlvaine buffer (pH 6.8) was introduced into a test tube, 0.05 ml of a tyrosinase solution (1 mg/ml) was added thereto, the resultant was mounted on a spectrophotometer capable of maintaining a constant temperature of 37° C., and the absorbance was measured at 475 nm with the elapse of time (once every minute between 0 min and 15 min). The results are shown in
A blank solution to which purified water (H2O) was added did not contain a substance that would inhibit tyrosinase activity. Thus, the amount of dopachrome rapidly increased during the period up to 2 minutes after the initiation of the reaction. In contrast, insignificant levels of inhibitory effects were observed with the aqueous solution of coumalin, and strong inhibitory effects were observed with the aqueous solution of coumalic acid. Under the present conditions, the inhibitory effects of the aqueous solution of 3H2P on tyrosinase activity were significantly stronger than those of coumalin and coumalic acid.
The inhibitory effects of coumalin (a-pyrone, Tokyo Chemical Industry Co., Ltd.), coumalic acid (Tokyo Chemical Industry Co., Ltd.), and 3142P on tyrosinase activity were examined.
In the experiment, 0.2 ml of an enzyme solution containing 72 units/ml tyrosinase (Sigma) was mixed with 1.0 ml of a substrate mixture (i.e., a 2:2:1 mixture of a 6 mM L-DOPA solution, the sample with the adjusted concentration, and phosphate buffer (pH 6.8)), the absorbance was measured at 475 nm at 37° C. at 0 min and 3 min, and the inhibition rate of tyrosinase activity was determined using the equation shown below.
Inhibition rate of tyrosinase activity (%)=(1−(the difference in the absorbance of the sample between 0 min and 3 min)/(the difference in the absorbance of the blank between 0 min and 3 min)×100
The samples were subjected to the experiment at the final concentrations of 0.3%, 0.1%, and 0.033%, and the inhibitory effects thereof on tyrosinase activity were compared. As a result, the inhibitory effects of 3H2P were found to be apparently stronger than those of coumalin and coumalic acid. The results are shown in
3-Hydroxy-4-pyrone, which has already been reported to have the skin-whitening effects (hereafter referred to as “3H4P,” it is also referred to as, for example, pyromeconic acid or pyrocomenic acid), is represented by the same molecular formula as 3H2P, although it is a compound classified as a γ-pyrone. A 3H4P reagent manufactured by Molekula was used.
In the experiment, 0.2 ml of an enzyme solution containing 72 units/ml tyrosinase (Sigma) was mixed with 1.0 ml of a substrate mixture (i.e., a 2:2:1 mixture of a 6 mM L-DOPA solution, the sample with the adjusted concentration, and phosphate buffer), the absorbance was measured at 475 nm at 37° C. at 0 min and 3 min, and the inhibition rate of tyrosinase activity was determined using the equation shown below.
Inhibition rate of tyrosinase activity (%)=(1−(the difference in the absorbance of the sample between 0 min and 3 min)/(the difference in the absorbance of the blank between 0 min and 3 min)×100
As a result of the measurement, kojic acid (i.e., a γ-pyrone) was found to exhibit the strongest inhibitory effects on tyrosinase activity, and the inhibitory effects of 3H2P on tyrosinase activity were found to be equivalent to those of 3H4P (
Inhibitory effects of 3H4P, 3H2P, and kojic acid on melanin production were compared. 3H4P manufactured by Molekula was used.
The experiment was carried out in the following manner.
B16 mouse melanoma 4A5 cells (RIKEN) were seeded at 5.0×104 cells/well on a 6-well plate and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS at 37° C. in the presence of 5% CO2. The medium was exchanged with fresh medium supplemented with the sample on the following day, and culture was conducted in the medium supplemented with the sample for an additional 5 days. The medium was removed 6 days after the initiation of culture, and the cells were collected by using trypsin. The collected cells were suspended in 1N sodium hydroxide, and melanin was extracted via heating. The absorbance of the melanin extract was measured at 405 nm, and the melanin level was quantified with the calibration curve of the melanin reagent (Sigma). In addition, the amount of proteins in the collected cells was determined using the DC Protein Assay KIT (BIO-RAD) and used as the indicator for the viable cell count. Through such measurement, the melanin level and the cell count were determined relative to levels observed in the control not supplemented with the sample, designated as 100. The results are shown in Table 2 and
As a result, the inhibitory effects of 3H4P on melanin production were found to be equivalent to those of kojic acid, and 3H2P was found to have stronger inhibitory effects on melanin production than such γ-pyrone compounds.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/JP2011/050986 | 1/20/2011 | WO | 00 | 7/18/2013 |
